Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes

Kastritis, Efstathios; Malandrakis, Panagiotis; Spiliopoulou, Vasiliki; Ntanasis‐Stathopoulos, Ioannis; Solia, Eirini; Theodorakakou, Foteini; Syrigou, Rodanthi; Kokkali, Nikoletta-Aikaterini; Migkou, Magdalini; Papaiakovou, Evangelos Eleutherakis; Fotiou, Despina; Ρούσσου, Μαρία; Kanellias, Nikolaos; Gavriatopoulou, Maria; Terpos, Evangelos; Dimopoulos, Meletios A.

doi:10.1182/blood-2022-165924

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reflecting the efficacy seen with selinexor‐dexamethasone in this later‐relapse setting, both studies showed notable response rates, with three of the 10 patients across the studies achieving ≥VGPR. The effectiveness of selinexor‐Vd and selinexor‐dexamethasone as later‐line therapy is also supported by real‐world data in a cohort of 44 patients who had received a median of 6 prior lines [79]; moderate activity was reported for the combinations, with respective ORRs of 35% and 24%, median PFS of 3.4 and 2.7 months, and a pooled median OS of 13.7 months. Two of 15 patients who were refractory to prior anti‐BCMA therapy responded to selinexor‐based therapy [79].…”

Section: Clinical Studies Of Selinexor In Multiple Myelomamentioning

confidence: 80%

“…The effectiveness of selinexor‐Vd and selinexor‐dexamethasone as later‐line therapy is also supported by real‐world data in a cohort of 44 patients who had received a median of 6 prior lines [79]; moderate activity was reported for the combinations, with respective ORRs of 35% and 24%, median PFS of 3.4 and 2.7 months, and a pooled median OS of 13.7 months. Two of 15 patients who were refractory to prior anti‐BCMA therapy responded to selinexor‐based therapy [79]. In a separate case report, a heavily pretreated patient with high‐risk disease who was refractory to bortezomib, ixazomib, and the immunomodulatory drugs achieved a VGPR with selinexor‐Vd, enabling them to proceed with allogeneic stem cell transplant [80].…”

Section: Clinical Studies Of Selinexor In Multiple Myelomamentioning

confidence: 80%

See 1 more Smart Citation

Selinexor: Targeting a novel pathway in multiple myeloma

Yee

Midha

et al. 2023

eJHaem

View full text Add to dashboard Cite

Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nuclear proteins to the cytoplasm, including tumour suppressor proteins. Inhibition of this process has demonstrated substantial antimyeloma activity in preclinical studies, both alone and in combination with established MM therapeutics. Based on a clinical trial programme encompassing multiple combination regimens, selinexor‐based therapy has been approved for the treatment of relapsed/refractory MM (RRMM), with selinexor‐dexamethasone approved in the later‐relapse setting for penta‐refractory patients and selinexor‐bortezomib‐dexamethasone approved for patients who have received ≥1 prior therapy. Here, we provide a comprehensive review of the clinical data on selinexor‐based regimens, including recent updates from the 2022 American Society of Hematology annual meeting, and summarise ongoing studies of this novel targeted agent in newly diagnosed MM and RRMM.

show abstract

Section: Clinical Studies Of Selinexor In Multiple Myelomamentioning

confidence: 80%